Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,55 CAD | -1,90% | -4,91% | -53,73% |
14/05 | Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Perdita netta Q1 di Aptose Biosciences in calo, grazie alla riduzione delle spese | MT |
Attività
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
William Rice
CEO | Chief Executive Officer | 65 | 28/10/13 |
C. Payne
DFI | Director of Finance/CFO | 61 | 27/06/22 |
Chief Tech/Sci/R&D Officer | - | 01/11/19 | |
Rafael Bejar
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/01/20 |
Investor Relations Contact | - | - | |
Marc Wiles
LAW | General Counsel | - | - |
Brooks Ensign
AUD | Comptroller/Controller/Auditor | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Denis Burger
BRD | Director/Board Member | 80 | 19/09/07 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 13/09/22 |
Mark Vincent
BRD | Director/Board Member | 71 | 19/09/07 |
Director/Board Member | 74 | 15/12/14 | |
William Rice
CEO | Chief Executive Officer | 65 | 28/10/13 |
Warren Whitehead
BRD | Director/Board Member | 71 | 07/04/11 |
Carol Ashe
BRD | Director/Board Member | 66 | 15/08/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 16 309 393 | 13 209 253 ( 80,99 %) | 0 | 80,99 % |
Coordinate società
Aptose Biosciences, Inc.
251 Consumers Road Suite 1105
M2J 4R3, Toronto
+647 479 9828
http://www.aptose.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-53,73% | 18,49 Mln | |
+64,23% | 62,59 Mrd | |
-2,31% | 41,18 Mrd | |
+44,36% | 40,29 Mrd | |
-8,29% | 27,9 Mrd | |
+11,97% | 26,21 Mrd | |
-21,16% | 19,09 Mrd | |
+7,54% | 13,08 Mrd | |
+27,17% | 12,05 Mrd | |
+25,72% | 12,26 Mrd |
- Borsa valori
- Azioni
- Azione APS
- Società Aptose Biosciences Inc.